Innovative Technology Solutions to Cancer Sample Preparation (R21)

The summary for the Innovative Technology Solutions to Cancer Sample Preparation (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Innovative Technology Solutions to Cancer Sample Preparation (R21): -Purpose. This Funding Opportunity Announcement (FOA) solicits developmental grant applications proposing research projects focused on the development and/or application of innovative technologies addressing various aspects of the preparation, purification, processing, and handling of cancer-relevant samples. The overall goal is to develop technologies that maximize the quality and utility of biospecimens for molecular analyses of cancer cells and their host environments without compromising donor/patient health. This FOA will also support the development of methods and tools to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control under diverse conditions. Responsive technologies encompass relevant methods, techniques, tools, instrumentation, and devices (but not software or informatics solutions). This FOA is part of the broader NCI-sponsored program Innovative Molecular Analysis Technologies (IMAT). Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides a brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-08-003. -Mechanism of Support. This FOA will utilize the NIH R21 award mechanism for exploratory (pilot) research projects. This FOA runs in parallel with another FOA of identical scientific scope, RFA-CA-08-010, that uses the NIH R33 award mechanism and is designed to fund Developmental Phase II projects. -Funds Available and Anticipated Number of Awards. The NCI intends to commit approximately 500,000 dollars in direct costs in Fiscal Year 2009 to fund up to five applications for the first year.